Form 4: Cyclo Therapeutics Director Francis Patrick Ostronic Reports Stock and Option Transactions

Director Francis Patrick Ostronic reports acquisition of common stock and stock options in Cyclo Therapeutics in lieu of cash compensation.

Summary

• On June 3, 2024, Francis Patrick Ostronic, a director of Cyclo Therapeutics, Inc., reported acquiring 10,743 shares of common stock.
• These shares were received in lieu of cash compensation for the first quarter of 2024, as per the company's non-employee director compensation policy.
• The shares were valued at $1.28 each, based on the closing price on June 3, 2024.
• Ostronic also acquired 15,562 stock options with an exercise price of $1.28.
• The options vest over a one-year period in equal quarterly installments and expire on June 3, 2034.
• Following these transactions, Ostronic beneficially owns 348,771 shares of common stock and 15,562 stock options.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of director compensation in the form of stock and options. The director taking stock instead of cash is a slightly positive signal.

Positives

• The director's acceptance of stock in lieu of cash compensation may be viewed positively as it aligns their interests with those of shareholders.

Industry Context

Form 4 filings are standard disclosures required by the SEC to ensure transparency in insider trading activities, providing investors with insights into the actions of company directors and officers.

Comparison to Industry Standards

• Director compensation packages often include a mix of cash, stock, and options to align management's interests with shareholder value.
• The vesting schedule of the options (quarterly over one year) is a common practice to incentivize continued service.
• The specific terms of the compensation package (number of shares, option exercise price) would need to be compared to peer companies to assess its competitiveness and appropriateness.

Stakeholder Impact

• The acceptance of stock in lieu of cash compensation by a director could be viewed positively by shareholders as it aligns interests.

Key Dates